More than 4,500 studies conducted, focusing on preclinical in vivo development. Vivotecnia consolidates its position as a strategic partner for the regulatory advancement of new drugs, biologics, and innovative products.
More than 4,500 studies conducted, focusing on preclinical in vivo development. Vivotecnia consolidates its position as a strategic partner for the regulatory advancement of new drugs, biologics, and innovative products.
